CERENOME, INC.
No SEC Form 4 filings for $CNSY in the last 30 days.
See all $CNSY insider activity →Cerenome, Inc. (CNSY) reached an in-network agreement with Florida Blue for its CNSide tests, adding ~6M covered lives and totaling ~164M. The deal is effective Oct 1, 2026, according to the company.
Cerenome's subsidiary, CNSide Diagnostics, launched two new CSF-based molecular profiling tests for cancer on October 12, 2026. The tests analyze DNA and RNA from cerebrospinal fluid, expanding the patient population served. The launch follows a peer-reviewed study showing molecular findings in 78.4% of specimens. Cerenome (Nasdaq: CNSY) aims to integrate diagnostics, therapeutics, and AI for CNS oncology.
Cerenome updated its investor presentation, reporting CNSide commercial progress with 24 ordering institutions and 362 tests YTD. It also highlighted upcoming REYOBIQ Phase 2 readouts and expected Medicare pricing in 2027. The company has 158M contracted covered lives and is building a 11,000-test CSF library.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CNSY (CERENOME, INC.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent CNSY coverage spans financial news, corporate actions and technology.
The new payer contract should boost revenue visibility and may drive the stock higher.
The launch adds a new revenue stream and may boost the stock as investors price in expanded test offerings.
The new data may boost investor confidence in Cerenome's commercial rollout and upcoming trial readouts.
The new billing guidance and Medicare pricing decision suggest incremental revenue growth.
Expanded reimbursement could boost revenue outlook for CNSide diagnostics.
AlphAI scores every news story that mentions CNSY with an AI model for sentiment and relevance, and aggregates insider trades from CERENOME, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cerenome, Inc. (CNSY) reached an in-network agreement with Florida Blue for its CNSide tests, adding ~6M covered lives and totaling ~164M. The deal is effective Oct 1, 2026, according to the company.
1 min readCerenome's subsidiary, CNSide Diagnostics, launched two new CSF-based molecular profiling tests for cancer on October 12, 2026. The tests analyze DNA and RNA from cerebrospinal fluid, expanding the patient population served. The launch follows a peer-reviewed study showing molecular findings in 78.4% of specimens. Cerenome (Nasdaq: CNSY) aims to integrate diagnostics, therapeutics, and AI for CNS oncology.
2 min readCerenome updated its investor presentation, reporting CNSide commercial progress with 24 ordering institutions and 362 tests YTD. It also highlighted upcoming REYOBIQ Phase 2 readouts and expected Medicare pricing in 2027. The company has 158M contracted covered lives and is building a 11,000-test CSF library.
1 min readCerenome (CNSY) reported Q3 2026 gross billings of $1.55M for CNSide Diagnostics. The company expects to cover 200M lives by early 2027 and launch new tests in Q4 2026. Annualized billing run rate is projected to reach $10M-$12M by Q4 2026, according to management.
2 min readADARx (ADRX) priced its IPO at $17/share, raising $446.3M, with AbbVie investing $100M. CNSY (CNSY) secured reimbursement with Blue Cross Blue Shield. JAGX (JAGX) completed a reverse stock split. AGL (AGL) expanded its partnership with Springfield Clinic. ONCO (ONCO) agreed to acquire Realbotix. All stocks traded higher.
2 min readCerenome's subsidiary CNSide Diagnostics signed an in-network agreement with Blue Cross Blue Shield of Michigan, expanding coverage to 5 million members. This deal increases CNSide's reimbursement coverage to 158 million lives nationwide, supporting physician adoption and patient access. Cerenome's stock is up 6.84% at $2.03.
1 min readCERENOME, INC. (CNSY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Capital will support continued CNSide ® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash r
1 min readCerenome, Inc. (Nasdaq: CNSY) secured a $20M financing facility with 3i, LP, with royalty-based repayments. The funds will support the commercial scale-up of its CNSide cerebrospinal fluid assay platform. Initial funding was provided at closing, with future tranches tied to milestones. The company forecasts a cash runway into 2028.
2 min readCERENOME, INC. (PSTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, August 14, 2026 – Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted th
6 min readPlus Therapeutics, Inc. (Nasdaq: PSTV) said its corporate rebrand to Cerenome will be completed on Aug. 3, 2026. The company will begin trading on Nasdaq under ticker CNSY. Cerenome plans an integrated CNS oncology approach combining its CNSide CSF diagnostics, investigational radiotherapeutic REYOBIQ, and proprietary data and AI platform.
3 min read
